Verquvo (vericiguat) / Bayer, Merck (MSD), Chong Kun Dang - LARVOL DELTA

VERIFICATION: Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression (clinicaltrials.gov) - P2 | N=238 | Recruiting | Sponsor: West China Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure

Mortality benefit and lifetime survival gains with vericiguat in HFrEF: Bayesian and actuarial analyses of the VICTOR trial. (PubMed, Eur J Heart Fail) - "In this post hoc analysis, Bayesian and actuarial methods provided hypothesis-generating evidence of a cardiovascular mortality benefit with vericiguat in HFrEF, an endpoint for which the trial was prospectively powered, that warrants prospective confirmation."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Estimating the Benefits of the Comprehensive Disease-modifying Pharmacological Treatment in Patients with Heart Failure. (PubMed, Card Fail Rev) - "The numbers needed to treat per year for the primary outcome, cardiovascular death and first heart failure hospitalisation were 10, 23 and 15, respectively. Our findings support the potential benefit of comprehensive therapy, with the incremental role of vericiguat likely greatest in higher-risk patients or those with recent worsening heart failure."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial. (PubMed, Eur J Heart Fail) - "In ambulatory patients with HFrEF receiving contemporary GDMT, we did not find convincing evidence that the neutral effect of vericiguat on cardiovascular death or first HF hospitalization was modified by GDMT class, dose attainment, or overall intensity, in a cohort with very high background GDMT use and limited power for interaction testing. These exploratory, hypothesis-generating findings do not establish independent efficacy or pathway additivity for vericiguat and should not be used to guide clinical recommendations regarding GDMT sequencing."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Renal Response To Vericiguat In Patients With Stable Chronic Heart Failure: A Prespecified Analysis Of VICTOR (HFSA 2026) - "In contrast to most guideline-directed medical therapies for HF, vericiguat did not influence the early rapid or sustained decline in eGFR. In addition, baseline eGFR did not modify the effects of vericiguat on clinical outcomes. Vericiguat may be an alternative treatment option for patients with HFrEF who cannot tolerate other guideline-directed medical therapies due to renal side effects."

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

The Effect Of Vericiguat On Sudden Cardiac Death Insights From The Victor Trial (HFSA 2026) - "In a population of patients with stable HFrEF with high use of GDMT and device therapy at baseline, vericiguat provided a clinically meaningful reduction in SCD risk. The observed reduction in SCD with vericiguat was mostly consistent across demographic characteristics, baseline comorbidities, and background GDMT and device therapy. The lack of escalating neurohormonal and hemodynamic stress or hospitalization prior to death suggests that vericiguat may lower SCD risk through mechanisms partially independent of congestion."

Cardiovascular

Vericiguat In Heart Failure With Reduced Ejection Fraction: A Systematic Review And Amstar-2 Quality Assessment Of Meta-analyses [Poster no. 717] (HFSA 2026) - No abstract available

Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Right Ventricular Reverse Remodeling With Vericiguat In Worsening Heart Failure [Poster no. 398] (HFSA 2026) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure

Finerenone Demonstrates Greater Reduction In Heart Failure Events Than Vericiguat And Omecamtiv Mecarbil: A Systematic Review [Poster no. 270] (HFSA 2026) - No abstract available

Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Vericiguat In Heart Failure With Reduced Ejection Fraction Management: A Meta-Analysis Beyond Guideline-Directed Medical Therapy [Poster no. 253] (HFSA 2026) - No abstract available

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

Non-Invasive Hemodynamic And Echocardiographic Changes Following Vericiguat Initiation In Heart Failure With Reduced Ejection Fraction: A Prospective Registry Study. (PubMed, Am J Cardiol) - "In conclusion, among real-world optimally treated patients with HFrEF, vericiguat initiation was associated with modest but statistically significant improvements in LVEF and LVOT VTI at 6 months. Favorable echocardiographic hemodynamic response appeared associated with improved subsequent clinical outcomes, supporting the role of non-invasive hemodynamic phenotyping to characterize response to soluble guanylate cyclase stimulation."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Phenotypic Clustering of Patients Treated with Vericiguat in Real-World Practice from the VERIFY-HF Cohort (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Real-world • Real-world evidence • Cardiovascular

The Vericiguat in Vasospastic Angina (ViVA) trial: a double-blind placebo-controlled randomized cross-over study (ESC 2026) - No abstract available

Clinical • Late-breaking abstract • Cardiovascular

Challenging perceptions: why add more to your HFrEF medication toolkit? (ESC 2026) - "Vericiguat ist zugelassen zur Behandlung von symptomatischer, chronischer Herzinsuffizienz bei erwachsenen Patienten mit reduzierter Ejektionsfraktion, die nach einem kürzlich aufgetretenen Dekompensationsereignis, das eine i.v.-Therapie erforderte, stabilisiert wurden.MA-M_VER-DE-0595-1. May 2026."

Cardiovascular • Congestive Heart Failure • Heart Failure

Why should soluble guanylate cyclase stimulation be part of your medication toolkit for heart failure with reduced ejection fraction? (ESC 2026) - "Sponsored by Bayer AG To underscore the need for timely therapeutic intervention in HFrEF; To explore the role of sGC stimulation as part of the contemporary HFrEF medication toolkit; and To discuss the practical use of vericiguat within the current treatment landscape...FOR HEALTHCARE PROFESSIONALS ONLY.HF, heart failure HFrEF, heart failure with reduced ejection fraction; i.v., intravenous/intravenös; sGC, soluble guanylate cyclase.MA-M_VER-DE-0594-1. May 2026."

Cardiovascular • Congestive Heart Failure • Heart Failure

Intrarenal venous flow improvement after vericiguat in worsening HFrEF: indirect effect from improvements in cardiac hemodynamics or possible pleiotropic effect? (PubMed, Int J Cardiol) - No abstract available

Journal • Cardiovascular

Soluble guanylate cyclase stimulators and activators: Chemistry, biology, and therapeutic advances. (PubMed, Eur J Med Chem) - "Although first-in-class sGC stimulators (e.g., riociguat, vericiguat) and activators (e.g., cinaciguat) have advanced into clinical use or development, most subsequent candidates continue to be refined to optimize efficacy, safety, and target selectivity. Specifically, these small molecules are classified and elaborated based on their mechanisms of action, structural characteristics, and development trajectories; for each category, the binding modes, structural features, and pharmacological activities of representative compounds are analyzed in detail, while their inherent advantages and limitations are critically evaluated. Collectively, this review offers valuable insights and guidance for the future research and development of safer, more effective, and more precisely targeted sGC modulators."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetic Retinopathy • Heart Failure • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Retinal Disorders

Vericiguat and cardiovascular outcomes in heart failure revisited: a bayesian reanalysis of 12,877 patients (ESC 2026) - "Conclusion This Bayesian reanalysis suggests that vericiguat was associated with a moderate probability of benefit across HF hospitalization and mortality outcomes, although the likelihood of a large clinically meaningful effect was low. These findings support a modest overall treatment effect in broad HF populations and underscore the importance of identifying patient subgroups most likely to derive greater benefit."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

The impact of soluble guanylate cyclase stimulator on cardiac and venous return characteristics: a framework analysis using generalized circulatory equilibrium (ESC 2026) - "The same protocol was performed using nitroglycerin (NTG, 5 µg/kg/min) in baroreflex-intact condition. Baroreflex impairment amplified vericiguat-induced reductions in SVR and AP. These findings suggest an increased risk of hypotension and underscore the importance of individualized therapy in heart failure patients with impaired baroreflex function."

Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension

Cardiac reverse remodelling of left heart during vericiguat therapy for high-risk HFrEF (ESC 2026) - "In high-risk HFrEF, 8 months of vericiguat therapy was associated with left-heart reverse remodelling (reduced LVESVI, increased LVEF, improved LVGLS and reduced LVMI) and enhanced LA function (increased LAEF and improved LA phasic strain), accompanied by biomarker reductions and improved patient-reported health status."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Prognostic Impact and Structural Recovery in HFrEF Patients on Vericiguat with PH and Tricuspid Regurgitation: Results from the VERISEC Registry (ESC 2026) - "Notably, a substantial proportion of survivors experience significant right-heart reverse remodeling, with reduced tricuspid regurgitation and normalized right ventricular dimensions. These findings suggest that Vericiguat may facilitate right-sided structural recovery by improving pulmonary vascular resistance and RV-PA coupling."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Association between up-titration of guideline-directed medical therapy and clinical outcomes in patients with chronic heart failure with reduced ejection fraction (ESC 2026) - "The GDMT score was calculated based on the use and dose of the quadruple therapy, ivabradine, vericiguat, and hydralazine/nitrates (Figure 1).1 Patients were classified into an up-titration group or a no up-titration group according to the change in GDMT score from baseline to 9 months after enrolment. In patients with HFrEF, up-titration of GDMT was independently associated with favourable clinical outcomes and LVRR. The GDMT score could facilitate optimisation of GDMT even in patients with chronic HFrEF."

Clinical • Clinical data • Cardiovascular • Congestive Heart Failure • Heart Failure

From trials to treatment: real-world vericiguat initiation and residual risk in Germany (ESC 2026) - "In German routine care, vericiguat is initiated predominantly in VICTORIA-like patients but also in a substantial VICTOR-like minority, including patients with recent ODI. Residual risk for death and HFH remains high, particularly after recent wHF, and implementation of foundational GDMT remains incomplete. ODI may represent an outpatient marker of risk comparable to recent HFH, even among ostensibly stable patients."

Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

Vericiguat improves MRI-assessed coronary endothelial function in patients with metabolic syndrome or type 2 diabetes mellitus (ESC 2026) - "There were no significant group differences in adverse events. Conclusion(s) Vericiguat improved MRI-assessed CEF in patients with diabetes or the metabolic syndrome providing the first in vivo human evidence that direct stimulation of sGC enhances CEF."

Clinical • Atherosclerosis • Cardiovascular • Coronary Artery Disease

Age-related differences in adverse events among vericiguat-treated patients with heart failure: insights from the VERIFY-HF registry (ESC 2026) - "In this real-world cohort of vericiguat-treated patients, the incidence of symptomatic hypotension did not increase with advancing age. However, renal and hematologic adverse events were more frequent in elderly patients, underscoring the necessity for careful monitoring in this vulnerable population."

Adverse events • Clinical • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension